



OPEN

SUBJECT AREAS:

CANCER

HAEMATOLOGICAL CANCER

ACUTE MYELOID LEUKAEMIA

TRANSCRIPTION

Received
24 April 2013Accepted
14 February 2014Published
3 March 2014

Correspondence and
requests for materials
should be addressed to
M.P.T. (mario.tschan@
pathology.unibe.ch)

* These authors
contributed equally to
this work.

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation

Elena A. Federzoni^{1,2,3*}, Magali Humbert^{1,2*}, Bruce E. Torbett³, Gerhard Behre⁴, Martin F. Fey^{1,5} & Mario P. Tschan^{1,2,5,6}

¹Experimental Oncology/Hematology, Department of Clinical Research, University of Bern, Bern, Switzerland, ²Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland, ³Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA, ⁴Department for Hematology and Oncology, University Hospital of Leipzig, Leipzig, Germany, ⁵Department of Medical Oncology, Inselspital, Bern University Hospital, ⁶Division of Experimental Pathology, Institute of Pathology, University of Bern, Bern, Switzerland.

The basic leucine zipper transcription factor CCAAT/enhancer binding protein alpha (*CEBPA*) codes for a critical regulator during neutrophil differentiation. Aberrant expression or function of this protein contributes to the development of acute myeloid leukemia (AML). In this study, we identified two novel unrelated *CEBPA* target genes, the glycolytic enzyme hexokinase 3 (*HK3*) and the krüppel-like factor 5 (*KLF5*) transcription factor, by comparing gene profiles in two cohorts of *CEBPA* wild-type and mutant AML patients. In addition, we found *CEBPA*-dependent activation of *HK3* and *KLF5* transcription during all-*trans* retinoic acid (ATRA) mediated neutrophil differentiation of acute promyelocytic leukemia (APL) cells. Moreover, we observed direct regulation of *HK3* by *CEBPA*, whereas our data suggest an indirect regulation of *KLF5* by this transcription factor. Altogether, our data provide an explanation for low *HK3* and *KLF5* expression in particular AML subtype and establish these genes as novel *CEBPA* targets during neutrophil differentiation.

The CCAAT/enhancer binding protein alpha (*CEBPA*) is a master regulator of myeloid differentiation that drives hematopoiesis towards the granulocytic lineage¹. The relevance of *CEBPA* in the maintenance of myeloid lineage is underlined by the fact that *Cebpa*-null mice lack the production of neutrophils and eosinophils². Not surprisingly, *CEBPA* functions are frequently disrupted in particular subtypes of acute myeloid leukemias (AML), thereby contributing to the differentiation arrest seen in AML blast cells. Several groups reported aberrant *CEBPA* function due to intragenetic mutations in 5–10% of AML patients (10–19% in normal karyotype-AML) (Reviewed in^{3–6}). Mutations in the *CEBPA* gene predominantly cause either a frame-shift at the N-terminus resulting in the truncated *CEBPA* isoform p30 with dominant negative function, or disrupt the basic zipper region at the C-terminus causing weakened DNA-binding (Reviewed in^{7,8}). Furthermore, most AML patients harbor *CEBPA* mutations on both alleles and these bi-allelic *CEBPA* mutated patients have a favorable clinical outcome as compared to *CEBPA*-wild-type or patients with a mono-allelic mutation (Reviewed in^{5,6}). Lastly, transcriptional repression mediated by leukemic fusion proteins or epigenetic alterations such as aberrant promoter hypermethylation further leads to low *CEBPA* expression in some AML patients⁹.

Our group recently reported a functional role for hexokinase 3 (*HK3*) and Krüppel-like factor 5 (*KLF5*) in the pathogenesis of AML^{10,11}. *HK3* (ATP:D-hexose 6-phosphotransferase) is a glycolytic enzyme most frequently expressed in myeloid cells and represents the dominant hexokinase in granulocytes accounting for 70–80% of total hexokinase activity^{10,12}. We identified *HK3* as a direct target of the transcription factors PU.1 and oncogenic fusion protein PML-RARA in acute promyelocytic leukemia (APL) characterized by the t(15;17) translocation. Inhibition of *HK3* impairs neutrophil differentiation of APL cells and promotes cell death upon anthracycline treatment. We found significantly reduced *HK3* expression not only in APL but also in other AML subtypes suggesting that additional mechanisms responsible for low *HK3* levels in AML are operative¹⁰.

We and others found that members of the Krüppel-like factor (KLF) family are often deregulated in primary AML patient samples¹¹. The KLF transcription factor family is composed of 17 members involved in diverse functions such as proliferation, self-renewal, differentiation and apoptosis¹³. Among the different KLFs inhibited in AML, *KLF5* was found to be essential for granulocytic differentiation^{11,14}. Low *KLF5* expression in AML can partially be




Figure 1 | *HK3* and *KLF5* expression is significantly downregulated in *CEBPA*-mutated AML patients. *HK3* (a) and *KLF5* (b) mRNA levels were measured by qPCR in total RNA extracted from primary AML (FAB M0-M7) blasts, CD34⁺ samples or granulocytes from healthy donors. Patient characteristics are summarized in Supplementary Table 1. *HK3* (c) and *KLF5* (d) levels in 154 patients from the Taskesen cohort with normal karyotype, expressing wild type *CEBPA* (WT), one allele mutated (SM) or two alleles mutated (DM). MWU: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$.

explained by hypermethylation of its promoter as shown in primary AML and in several AML cell line models¹⁴. Still unclear is how *KLF5* is transcriptionally regulated during granulocytic differentiation.

In this study we describe two novel *CEBPA* target genes, the glycolytic enzyme *HK3* and the transcription factor *KLF5*, both of which are significantly downregulated in *CEBPA*-mutated AML patients.

Results

Low *HK3* and *KLF5* expression is associated with *CEBPA*-mutated AML. *CEBPA* is a master regulator of myeloid differentiation, whose expression peaks in the granulocyte-monocyte progenitor cell stage, and diminishes during terminal granulocyte differentiation³. Most importantly, in different AML subtypes *CEBPA* expression or function is inhibited by a variety of mechanisms^{3,5,6}. In an attempt to test whether *HK3* and *KLF5*, two genes with a recently discovered role in APL differentiation^{10,11,14}, are novel *CEBPA* target genes, we compared their expression in a total of 90 *CEBPA*-mutated or *CEBPA* wild-type AML patients. *HK3* and *KLF5* were below the detection limit in 11 and 16 AML patient samples, respectively. We compared *HK3* mRNA expression in CD34⁺ samples (n = 4) to 74 *CEBPA*-wt and 5 *CEBPA*-mutated AML samples. *KLF5* expression in 4 CD34⁺ samples was compared to 70 *CEBPA*-wt and 4 *CEBPA*-mutated AML

samples. A detailed analysis of *HK3* and *KLF5* mRNA levels in primary AML (FAB M0-M7) patient samples revealed a significantly lower expression of *HK3* and *KLF5* in *CEBPA*-mutated as compared to *CEBPA* wild-type AML samples ($p < 0.01$) (Figure 1a–b). As seen for other *CEBPA* target genes identified by screening AML patient cohorts, our results suggest that disrupting *CEBPA* function impairs *HK3* and *KLF5* expression¹⁵. Next, we confirmed that *HK3* and *KLF5* expression is significantly lower in *CEBPA*-mutated, but not *CEBPA* wild-type patients from analysis of a second AML patient cohort (n = 154). Since these cohorts contained patients with *CEBPA* single (SM) or double mutations (DM), we could address whether single or double mutations alter *HK3* or *KLF5* expression¹⁶. We found that *HK3* or *KLF5* expression was not significantly different from patient's samples with either *CEBPA* SM or DM (Figure 1c–d). Taken together, our findings indicate that loss of *HK3* or *KLF5* expression correlated with *CEBPA* mutations, irrespective of single or double *CEBPA* mutations, whereas enhanced expression of *HK3* or *KLF5* correlated with wild-type *CEBPA* expression.

CEBPA-dependent induction of *HK3* and *KLF5* during neutrophil differentiation of APL cells. To experimentally test whether




Figure 2 | Genetic inhibition of *CEBPA* impairs *HK3* and *KLF5* upregulation during neutrophil differentiation of APL cells. (a) NB4 or HT93 APL cell lines were stably transduced with pLKO.1 lentiviral vectors expressing non-targeting or two independent *CEBPA*-targeting shRNAs. APL control and *CEBPA* knockdown cells were differentiated with 1 μ M ATRA for 4 days. Knockdown efficiency in NB4 (top panels) or HT93 (bottom panels) APL cells was validated by qPCR. *CEBPA* mRNA expression was normalized to the housekeeping gene *HMBS* and is shown as n-fold changes compared to untreated SHC002 control cells. *HK3* (b) and *KLF5* (c) mRNA expression in NB4 or HT93 APL cells was determined by qPCR and analyzed as in 2a. Impairment in granulocytic differentiation of *CEBPA* knockdown cells was shown by a reduction of the neutrophil marker granulocyte colony-stimulating factor receptor (*GCSFR* or *CSF3R*) (d) Data represent the mean \pm s.d. of at least three independent experiments. (e), (f) *CEBPA* Knockdown efficiency at the protein level in NB4 and HT93 APL cells was confirmed by western blotting. GAPDH is shown as a loading control. MWU: * $p < 0.05$, ** $p < 0.01$ and *** $p < 0.001$.

loss of *CEBPA* mRNA alters *HK3* and *KLF5* expression, we knocked down *CEBPA* in the two APL cell line models NB4 and HT93. This was accomplished using lentiviral vectors expressing two independent short hairpin (sh)RNAs targeting the *CEBPA* gene. Knockdown efficiency was evaluated by qPCR and Western blotting (Figures 2a, e and f). After 4 days of treatment with 1 μ M ATRA to promote neutrophil differentiation, we observed significantly reduced *HK3* and *KLF5* mRNA levels in the NB4 and HT93 *CEBPA* knockdown cell lines as compared to the control cells (Figures 2b and c). We evaluated *G-CSFR* expression in *CEBPA* knockdown cells (Figure 2d) to validate inhibition of ATRA-induced neutrophil differentiation, while induction of *CEBPE*, a direct *CEBPA* regulated gene¹⁷, was measured as an additional control

(Supplementary Figures S1a and b). Our results clearly demonstrate that the upregulation of *HK3* and *KLF5* during neutrophil differentiation of APL cells is *CEBPA*-dependent.

***CEBPA* binding to the *HK3* or *KLF5* promoters activates transcription.** Our findings prompted us to investigate if *HK3* and *KLF5* are direct transcriptional targets of *CEBPA*. To this end, we first analyzed the genomic regions surrounding exon 1 of these genes for putative *CEBPA* binding sites using MatInspector 8.0. We identified two putative *CEBPA* binding sites in both the *HK3* and the *KLF5* genomic regions analyzed (Figure 3a and c). Chromatin immunoprecipitation (ChIP) revealed binding of *CEBPA* at positions +821/+2963 and -385/-1576 relative to the transcriptional




Figure 3 | CEBPA binds to and activates the *HK3* and the *KLF5* promoters. Schematic representation of a 6 kb human *HK3* (a) and a 5 kb human *KLF5* (c) genomic regions retrieved from an online database. MatInspector software predicted two putative CEBPA binding sites (squares) in the DNA sequences analyzed. *In vivo* binding of CEBPA to these CEBPA consensus sites in the *HK3* (b) or *KLF5* (d) genomic regions was shown by chromatin immunoprecipitation (ChIP) in NB4 APL cells. As a negative control for the different pull downs, absence of *GAPDH* amplification is shown. *unspecific band, primer dimer. Two *HK3* (e–f) and one *KLF5* genomic region (g) containing the CEBPA binding sites were PCR amplified from genomic DNA of NB4 cells using proofreading Pfu DNA polymerase and cloned into the pGL4.10-basic vector. H1299 cells were transiently transfected with 40 ng of either *HK3* promoter reporter construct A (e), construct A with mutated CEBPA binding site (f, wild-type GAAAGAC, mutated GGTCGAC) or the *KLF5* promoter reporter construct (g), together with pcDNA3.1 empty vector or increasing concentrations (40–80–120 ng) (e,g) or 80 ng of CEBPA expression vector (f). The promoter activity is shown as relative light units (RLU) relative to pcDNA3.1 control transfected cells. Results are the means \pm s.d. of at least triplicate transfections. MWU: ** $p < 0.01$, *** $p < 0.001$.

start site on the *HK3* and *KLF5* genomic regions, respectively (Figures 3b and d). We next asked whether CEBPA activates *HK3* and *KLF5* transcription from these sites using promoter reporter assays. CEBPA co-expression with the different luciferase promoter reporters resulted in a significant, dose-dependent activation of *HK3* promoter A (up to 37-fold) and *KLF5* (up to 11-fold) transcription, respectively (Figures 3e and g). The *HK3* promoter B containing the CEBPA binding site +2963 was only induced 1.5-fold (Supplementary Figure S2a). To confirm the specific CEBPA-induction of the promoter activity we mutated the CEBPA binding sites on the *HK3* promoter A and the *KLF5* promoter. Indeed, inactivating the CEBPA binding site in the *HK3* promoter significantly inhibited transcriptional inhibition (Figure 3f). Surprisingly, however, introducing single or double CEBPA binding sites mutations in the *KLF5* promoter did not attenuate transcriptional activity of the reporter construct (Supplementary Figure S2b).

Ectopic expression of CEBPA significantly induces *HK3* and *KLF5* transcription. To confirm CEBPA-dependent transcriptional regulation of *HK3* and *KLF5*, we overexpressed CEBPA in HT93 APL cells by transiently transfecting a CEBPA expression

plasmid. Ectopic expression of CEBPA in HT93 cells resulted in a significant 5.5- and 12.3-fold induction of *HK3* and *KLF5* gene expression, respectively (Figures 4a and b). CEBPA transfection efficiency was assessed by qPCR and Western blotting (Figure 4d and e). In addition, induction of the direct CEBPA target *CEBPE* was measured as a positive control of CEBPA activity (Figure 4c). Next, we used K562 leukemic cell lines expressing 4-OHT inducible full-length CEBPA (CEBPA-p42-estrogen receptor (ER)), a truncated isoform (CEBPA-p30-ER), or a p42 isoform with a mutation preventing interaction with E2F and neutrophil differentiation (CEBPA-BRM2-ER). After 24 h of 4-OHT treatment, we observed a significant 2.5-fold transcriptional activation of *KLF5* ($p < 0.05$) upon CEBPA-p42-ER activation only, but not in ER control, nor in CEBPA-p30-ER, or mutated CEBPA-BRM2-ER activated K562 cells (Figure 4f), suggesting that induction of *KLF5* is a specific function of the full length CEBPA p42 isoform. Interestingly, *HK3* mRNA was not detectable in K562 cells indicating that different HK isoforms may be active in these cells. Induction of *CEBPE* was measured as a positive control (Figure 4g). Altogether, our findings demonstrate that CEBPA is a crucial positive regulator of *HK3* and *KLF5* during granulocytic differentiation.




Figure 4 | Ectopic expression of CEBPA activates *HK3* and *KLF5* transcription. (a–e) HT93 cells were transiently transfected with pcDNA3.1 empty control or a CEBPA expression vector. *HK3* (a) and *KLF5* (b) mRNA expression was quantified by qPCR. Data were normalized to HMBS and are shown as n-fold regulation as compared to control transfected cells. Induction of *CEBPE* mRNA, a direct target gene of *CEBPA*, was measured as a positive control for CEBPA activity (c). Results are the means \pm s.d. of at least triplicate transfections. CEBPA transfection efficiency was measured by qPCR (d) and western blotting (e). GAPDH is shown as a loading control. (f–g) Different CEBPA-ER fusion constructs were induced by treating the respective K562 cell lines with 5 μ M Tamoxifen for 24 h. *HK3* (f) or *KLF5* (g) mRNA expression was quantified by qPCR as in 2a. Expression of the CEBPA target *CEBPE* was measured as positive control for CEBPA activation in wildtype CEBPA p42 expressing K562 cells. MWU: * $p < 0.05$, ** $p < 0.01$.

Discussion

Reduced CEBPA expression or loss of function mutations are commonly observed in AML suggesting that the deregulation of *CEBPA* function is a major event in the development of AML^{18–20}. Identifying new CEBPA target genes and associated CEBPA-dependent pathways in myeloid differentiation may provide novel insights into the differentiation block as well as into ancillary cellular functions found in AML. Interestingly, *CEBPA* has been described as a pivotal regulator of various metabolic processes in different cell types²¹. Nevertheless, whether CEBPA regulates metabolic activity in myeloid cells is of yet unclear. Our findings now link *CEBPA* to glycolysis via direct positive regulation of the glycolytic enzyme *HK3*. We have previously shown that *HK3* expression is repressed in AML, particularly in APL, where low *HK3* levels are the result of PML-RARA repression and low expression of its positive regulator PU.1¹⁰. Our results demonstrate that CEBPA is an additional critical regulator of *HK3* expression in AML and during neutrophil differentiation of APL cells. Furthermore, our findings show that the lowest *HK3* expression is found in *CEBPA* mutated patients and may contribute to the differentiation block in this AML subtype.

In general, AML is defined by a block in differentiation and an increased proliferation of immature myeloid progenitors¹⁸. Additionally, loss of CEBPA-mediated cell-cycle arrest is crucial for the development of AML^{15,22,23}. Since *KLF5* regulates genes involved in cell cycle regulation and apoptosis, it may represent a relevant downstream effector of CEBPA-induced cell cycle arrest (reviewed in²⁴). In the myeloid lineage, *KLF5* induces differentiation and functions as a tumor suppressor and its low expression in AML is partially explained by epigenetic silencing^{11,14,25}. Importantly, low *KLF5* expression is associated with poor overall survival²⁶. In this study, we suggest an additional mechanism for low *KLF5* levels in AML that is loss of positive regulation of *KLF5* due to impaired *CEBPA* function. Since mutating the CEBPA binding sites in the *KLF5* promoter constructs did not change the responsiveness of these reporters to CEBPA expression, *CEBPA* may indirectly activate *KLF5* transcription. The *KLF5* promoter lacks a TATA box, but contains a GC-rich region that is activated by the transcription factor Sp1²⁷. Moreover, CEBPA can functionally interact with Sp1, e.g. in regulating the *CD11c* integrin gene²⁸. We propose, that CEBPA induces *KLF5* transcription, similarly to *CD11c* regulation, via Sp1.



In conclusion, we identified *HK3* and *KLF5* as novel CEBPA-regulated genes in AML and during APL differentiation underlining their tumor suppressor function in AML as well as their role in granulopoiesis.

Methods

Patient samples, cell lines and cell culture conditions. Fresh leukemic blast cells from untreated AML patients at diagnosis obtained at the Inselspital Bern (Switzerland) were classified according to the French-American-British (FAB) classification and cytogenetic analysis. All leukemic samples displayed a blast count of >90% after separation of mononuclear cells using a Ficoll gradient (Lymphoprep™, Axon Lab AG, Switzerland) as described previously^{10,11}. PBMC and granulocytes obtained from normal, healthy donors were isolated using a Ficoll gradient.

The human acute promyelocytic leukemia (APL) cell lines NB4 and HT93 were maintained in RPMI-1640 (Sigma-Aldrich) with 10% fetal calf serum (FCS, Biochrom, AG), 50 U/mL penicillin and 50 µg/mL streptomycin (Sigma-Aldrich) in a 5% CO₂-95% air humidified atmosphere at 37°C.

For differentiation experiments, NB4 cells were seeded at a density of 0.2×10^6 /ml and treated with 1 µM *all-trans* retinoic acid (ATRA, dissolved in DMSO, Sigma Aldrich) as indicated. Successful neutrophil differentiation was assessed by light microscopy using May-Grünwald-Giemsa (Merck, Darmstadt, Germany) stained cells and by surface expression of the differentiation marker CD11b (Immunotools). Briefly, 5×10^5 cells were collected, washed, and incubated with monoclonal mouse phycoerythrin (PE)-labeled anti-human-CD11b for 20 min at 4°C. Fluorescence intensity was then measured by a FACS Calibur flow cytometer (Becton Dickinson, Basel, Switzerland) and analyzed using FlowJo Software.

K562-CEBPA-p42-ER, K562-CEBPA-p30-ER, K562-CEBPA-BRM2-ER and K562-ER were kindly provided by Prof. G. Behre and were maintained in RPMI-1640 supplied with 10% fetal calf serum (FCS), 50 U/mL penicillin and 50 µg/mL streptomycin in a 5% CO₂-95% air humidified atmosphere at 37°C. K562 CEBPA-ER cells were differentiated as described¹⁵ by addition of 5 µM 4-OHT (Sigma-Aldrich).

Chromatin immunoprecipitation (ChIP). ChIP was performed using the ChIP-IT Express Chromatin Immunoprecipitation Kit (ChIP-IT Express, Active Motif, Rixensart, Belgium) according to the manufacturer's recommendations. For immunoprecipitation, an anti-CEBPA antibody (sc-61X Santa Cruz, CA, US) was used. Antibodies against acetyl-histone H3 (Stratagene, La Jolla, CA, US) and IgG (PP64B, Upstate, Millipore) served as positive and negative controls, respectively. PCR was performed using the following primers: HK3 promoter A, F: GGGCTACTTGGGGATTGCTTCACA, R: ACGTGTCTTTCTCAAGGCCAGC; HK3 promoter B, F: TCAGCCTTCCAGTGCTCTCTCA, R: CTGTAGCAGTC-AACACAGAGGCC; KLF5 promoter A, F: 5'-ACAGCATGGGGCTGCTTGGT-3', R: 5'-TGCCTTCAGAGATGGCTGATGAC-3'; KLF5 promoter B, F: 5'-GCGCCCTACCTAGCTGCCT-3', R: 5'-GGTGGAGACGCGCGAGGAGA-3'. As a negative control for the different pulldowns, absence of *GAPDH* amplification is shown²⁹.

Human *HK3* and *KLF5* promoter reporter assays and mutagenesis. Two *HK3* promoter regions and one *KLF5* promoter region containing the CEBPA binding sites were PCR amplified from genomic DNA of NB4 APL cells using proof reading Pfu DNA polymerase (Promega, Dübendorf, Switzerland) and cloned into the pGL4.10-basic vector (Promega). All mutants were introduced using the QuickChange site-directed mutagenesis system (Agilent, CA, USA) according to the manufacturer's instructions. Promoter transactivation assays were performed as previously described¹⁰. Briefly, H1299 cells were transiently transfected with 40 ng of the promoter reporter constructs together with pcDNA3.1 empty or CEBPA expression vector. The promoter activity was measured using the Dual-Luciferase Reporter Plasmid System (Promega) and is shown as relative light units (RLU) relative to pcDNA3.1 control transfected cells.

TaqMan Low Density Array (LDA) and real-time quantitative reverse transcription PCR (qPCR). RNA extraction, RT-PCR and LDA measurements, as well as data analysis were done as described^{10,11}. Total RNA was extracted using the RNeasy Mini Kit and the RNase-Free DNase Set according to the manufacturer's protocol (Qiagen, Hombrechtikon, Switzerland). Total RNA was reverse transcribed using random primers (Roche Diagnostics) and M-MLV reverse transcriptase (Promega). PCR and fluorescence detection were performed using the ABI PRISM® 7500 Sequence Detection System (Applied Biosystems, Rotkreuz, Switzerland). Data represent log₂ expression levels and the measured cycle threshold (Ct) values were normalized to the expression levels of the housekeeping genes *HMBS* and *ABL1*. For quantification of *KLF5*, *CEBPA*, *CEBPE* and *G-CSFR* mRNA in human cells we used Taqman® Gene Expression Assays Hs00156145_m1, Hs00269972_s1, Hs00357657_m1, and Hs00167918_m1, (Applied Biosystems), respectively. *HMBS* as well as *ABL1* primers and probes have been previously described^{10,11}.

Cell lysate preparation and Western blotting. Whole cell extracts were prepared using RIPA lysis buffer supplemented with 8 M UREA according to the protocol found at www.abcam.com. 40–60 µg total protein was loaded on a 10% or 12% denaturing polyacrylamide gel. Blots were incubated with the primary antibodies in TBS 0.05% Tween-20/5% milk overnight at 4°C, incubated with secondary antiserum

or -rabbit antibody at 1:5–10,000 for 1 h at room temperature, and analyzed using the Odyssey infrared imaging system detection (Li-Cor Biosciences). Primary antibodies used were anti-CEBPA (Abcam) 1:500 and anti-GAPDH (Millipore) 1:5'000. Secondary antibodies used were goat anti-rabbit IRDye® 800CW and goat anti-mouse IR Dye® 680LT (Li-Cor Biosciences).

Transient transfection. HT93 cells were transiently transfected using a cell nucleofector kit (Amaxa Biosystems) according to the manufacturer's instructions. Briefly, the cells were washed in PBS and then resuspended in nucleofector solution to a final concentration of 2×10^6 cells per 100 µl each. Afterwards, the cell suspension was mixed with plasmid DNA pcDNA3.1 either empty, as a negative control, or expressing CEBPA, using the program X-01 and incubated at 37°C and 5% CO₂ for 24 h.

Lentivirus preparation and transduction of target cells. pLKO.1-puro lentiviral vectors expressing shRNAs targeting CEBPA (shCEBPA_1: NM_004364.2-171s1c1 or shCEBPA_2: NM_004364.2-1335s1c1) or the control vector (SHC002) were purchased from Sigma-Aldrich. All vectors contain a puromycin antibiotic resistance gene for selection of transduced mammalian cells. Lentivirus production and transduction were done as described^{10,11}. Transduced HT93 and NB4 cells were selected with 1.5 µg/ml puromycin for 4 days and knockdown efficiency was validated by qPCR.

Statistical analysis. Nonparametric Mann-Whitney-U (MWU) tests were applied to compare the difference between two groups using GraphPad Prism 4 software (Graph Pad Software, San Diego, CA). P-values < 0.05 were considered statistically significant. *HK3* and *KLF5* promoter regions were retrieved from an online database (www.ncbi.nlm.nih.gov), while the putative CEBPA binding sites were predicted by MatInspector (www.genomatix.de).

- Radomska, H. S. *et al.* CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. *Mol. Cell. Biol.* **18**, 4301–4314 (1998).
- Zhang, D. E. *et al.* Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 569–574 (1997).
- Tenen, D. G. Disruption of differentiation in human cancer: AML shows the way. *Nat. Rev. Cancer* **3**, 89–101 (2003).
- Zeisig, B. B., Kulasekararaj, A. G., Mufti, G. J. & So, C. W. E. Snapshot: Acute myeloid leukemia. *Cancer Cell* **22**, 698–698.e1 (2012).
- Paz-Priel, I. & Friedman, A. C/EBPα dysregulation in AML and ALL. *Crit Rev Oncog* **16**, 93–102 (2011).
- Pabst, T. & Mueller, B. U. Complexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia. *Clin Cancer Res* **15**, 5303–5307 (2009).
- Gombart, A. F. *et al.* Mutations in the Gene Encoding the Transcription Factor CCAAT/Enhancer Binding Protein A in Myelodysplastic Syndromes and Acute Myeloid Leukemias. *Blood* **99**, 1332–1340 (2002).
- Martelli, M. P., Sportoletti, P., Tiacci, E., Martelli, M. F. & Falini, B. Mutational landscape of AML with normal cytogenetics: biological and clinical implications. *Blood Rev.* **27**, 13–22 (2013).
- Figuerola, M. E. *et al.* MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. *Blood* **114**, 3448–3458 (2009).
- Federzoni, E. A. *et al.* PU.1 is linking the glycolytic enzyme HK3 in neutrophil differentiation and survival of APL cells. *Blood* **119**, 4963–4970 (2012).
- Humbert, M. *et al.* Deregulated expression of Kruppel-like factors in acute myeloid leukemia. *Leuk. Res.* **35**, 909–913 (2011).
- Rijksen, G. S. G., Rijksen, G., Staal, G. E., Beks, P. J. *et al.* Compartmentation of hexokinase in human blood cells. Characterization of soluble and particulate enzymes. *Biochim. Biophys. Acta* **719**, 431–7 (1982).
- McConnell, B. B. & Yang, V. W. Mammalian Krüppel-like factors in health and diseases. *Physiol. Rev.* **90**, 1337–1381 (2010).
- Diakiw, S. M. *et al.* The granulocyte-associated transcription factor Krüppel-like factor 5 is silenced by hypermethylation in acute myeloid leukemia. *Leuk. Res.* **36**, 110–116 (2012).
- Pulikkan, J. A. *et al.* C/EBPα regulated microRNA-34a targets E2F3 during granulopoiesis and is down-regulated in AML with CEBPA mutations. *Blood* **116**, 5638–5649 (2010).
- Taskesen, E. *et al.* Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. *Blood* **117**, 2469–2475 (2011).
- D'Alo', F. *et al.* The amino terminal and E2F interaction domains are critical for C/EBPα-mediated induction of granulopoietic development of hematopoietic cells. *Blood* **102**, 3163–3171 (2003).
- Rosenbauer, F. & Tenen, D. G. Transcription factors in myeloid development: balancing differentiation with transformation. *Nat. Rev. Immunol.* **7**, 105–117 (2007).
- Nerlov, C. C/EBPα mutations in acute myeloid leukaemias. *Nature Reviews Cancer* **4**, 394–400 (2004).
- Schlenk, R. F. *et al.* Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. *N. Engl. J. Med.* **358**, 1909–1918 (2008).



21. Yang, J. *et al.* Metabolic response of mice to a postnatal ablation of CCAAT/enhancer-binding protein alpha. *J. Biol. Chem.* **280**, 38689–38699 (2005).
22. Bereshchenko, O. *et al.* Hematopoietic stem cell expansion precedes the generation of committed myeloid leukemia-initiating cells in C/EBPalpha mutant AML. *Cancer Cell* **16**, 390–400 (2009).
23. Kirstetter, P. *et al.* Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. *Cancer Cell* **13**, 299–310 (2008).
24. Dong, J.-T. & Chen, C. Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. *Cell. Mol. Life Sci.* **66**, 2691–2706 (2009).
25. Karp, J. E. & Rassool, F. V. KLFs and ATRA-induced differentiation: New pathways for exploitation. *Leukemia Research* **35**, 846–847 (2011).
26. Diakiw, S. M. *et al.* Methylation of KLF5 contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival. *Br. J. Haematol.* **161**, 884–888 (2013).
27. Chen, C. *et al.* Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells. *Gene* **330**, 133–142 (2004).
28. López-Rodríguez, C., Botella, L. & Corbí, A. L. CCAAT-enhancer-binding proteins (C/EBP) regulate the tissue specific activity of the CD11c integrin gene promoter through functional interactions with Sp1 proteins. *J. Biol. Chem.* **272**, 29120–29126 (1997).
29. Kaeser, M. D. & Iggo, R. D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 95–100 (2002).

Acknowledgments

We thank D. Shan for excellent technical support and Dr. Diogo F.T. Veiga for his help in analyzing the public available AML patient data. This study was supported by grants from the Swiss National Science Foundation 31003A_129702 (to M.F.F. and M.P.T.) and 31003A_143739 (to M.P.T.), the Marlies-Schwegler Foundation, the Ursula-Hecht-Foundation for Leukemia Research, and the Bernese Foundation of Cancer Research (to M.F.F.), the Werner and Hedy Berger-Janser Foundation of Cancer Research (to M.F.F. and M.P.T.), the Bern University Research Foundation (to M.P.T.), and the Joyce Klein Stock Gift and NIH R01HL091219 (to B.E.T.).

Author contributions

E.A.F. and M.H. performed the experimental research, analyzed the data and drafted the article. G.B. provided essential CEBPA reagents and revised the article. M.F.F. and B.E.T. instigated the experimental design and revised the drafted article. M.P.T. designed the project, wrote the paper and gave final approval of the submitted manuscript.

Additional information

Supplementary information accompanies this paper at <http://www.nature.com/scientificreports>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Federzoni, E.A. *et al.* CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation. *Sci. Rep.* **4**, 4261; DOI:10.1038/srep04261 (2014).



This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported license. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/3.0>